Atopic dermatitis (eczema) trials in Poland

In Poland 27 Also abroad 251

27 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Where
Gdansk, Krakow, Łódź, Ostrowiec Świętokrzyski, Rzeszów, Tarnów, Warsaw
Age
6 months to 11 years
People
195 worldwide
Run by
LEO Pharma
See details and how to joinNCT06311682 · EU 2023-503630-44-00
Phase 3Not yet taking people in Poland
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
Where
Cracow, Gdansk, Katowice, Kraków, Lodz, Łódź, Lublin, Szczecin, Torun, Warsaw, Warszawa, Wroclaw
People
150 worldwide
Run by
Hunan Mabgeek Biotech Co. Ltd.
See details and how to join2025-525022-35-00 · EU 2025-525022-35-00
Phase 1Taking people
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Where
Chorzów, Katowice, Kielce, Lodz, Szczecin
Age
18 years to 70 years
People
119 worldwide
Run by
Pfizer
See details and how to joinNCT06564389 · EU 2025-524150-34-00
Phase 3Taking people
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Where
Chorzów, Katowice, Krakow, Lodz, Lublin, Ostrowiec Świętokrzyski, Warsaw
Age
2 years to 11 years
People
450 worldwide
Run by
Pfizer
See details and how to joinNCT06807281 · EU 2023-509124-18-00
Phase 2Taking people
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Where
Cracow, Gdansk, Katowice, Kielce, Szczecin
Age
18 years to 64 years
People
165 worldwide
Run by
Pfizer
See details and how to joinNCT07216027 · EU 2025-522965-31-00
Phase 2Taking people
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Where
Gdansk, Katowice, Krakow, Lodz, Lublin, Sosnowiec, Szczecin, Warsaw, Wroclaw
Age
18 years and over
People
350 worldwide
Run by
Apogee Therapeutics, Inc.
See details and how to joinNCT07003425
Phase 2Taking people
A Phase 2b Study of the Effects of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis
Where
Bydgoszcz, Chojnice, Gdansk, Katowice, Kielce, Lublin, Piotrkow Trybunalski, Poznan, Szczecin, Warsaw, Wroclaw
Age
18 years and over
People
138 worldwide
Run by
Apollo Therapeutics Limited
See details and how to join2026-525673-39-00 · EU 2026-525673-39-00
Phase 3Enrolling by invitation
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Where
Cracow, Gdansk, Lodz, Warsaw
Age
6 months to 18 years
People
338 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05735483 · EU 2022-501478-21-00
Phase 2Not yet taking people in Poland
A study to investigate the efficacy and safety of TRIV-573 compared with placebo in participants with moderate to severe atopic dermatitis
Where
Katowice, Kielce, Lublin, Mikolow, Nowa Sol, Poznan, Szczecin, Warsaw, Wroclaw
Age
18 years and over
People
43 worldwide
Run by
Triveni Bio Inc.
See details and how to join2026-526485-25-00 · EU 2026-526485-25-00
Phase 3Taking people
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Where
Bialystok, Białystok, Chorzów, Cracow, Gdansk, Katowice, Lodz, Lublin, Poznan, Szczecin, Warszawa, Wroclaw
Age
12 years and over
People
510 worldwide
Run by
Nektar Therapeutics
See details and how to joinNCT07690371 · EU 2025-524925-42-00
Phase 3Not yet taking people in Poland
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
Where
Gdansk, Rzeszów, Warsaw, Wroclaw
Age
12 years and over
People
230 worldwide
Run by
Almirall, S.A.
See details and how to joinNCT07873801 · EU 2025-525133-31-00
Phase 1Taking people
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
Where
Lodz, Rzeszów, Warsaw, Wroclaw
Age
18 years to 72 years
People
237 worldwide
Run by
Bambusa Therapeutics
See details and how to joinNCT06808477 · EU 2025-522918-23-00
Phase 2Not yet taking people in Poland
A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
Where
Cracow, Gdansk, Lublin, Piotrkow Trybunalski, Sosnowiec, Warsaw, Wroclaw
Age
18 years and over
People
96 worldwide
Run by
Enveda Therapeutics Inc.
See details and how to join2026-526184-38-00 · EU 2026-526184-38-00
Phase 2Taking people
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Where
Katowice, Lodz, Lublin, Warsaw
Age
18 years to 100 years
People
224 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06947993 · EU 2024-519081-49-00
Phase 3Taking people
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Where
Chorzów, Katowice, Krakow, Łódź, Lublin, Ostrowiec Świętokrzyski, Warsaw
Age
6 years to 11 years
People
150 worldwide
Run by
Pfizer
See details and how to joinNCT06807268 · EU 2023-509121-51-00
Phase 3Taking people
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Where
Bialystok, Chorzów, Cracow, Gdynia, Iwonicz-Zdroj, Krakow, Lublin, Malbork, Rzeszów, Szczecin, Tarnów, Torun, Warsaw, Warszawa
Age
12 years and over
People
510 worldwide
Run by
Nektar Therapeutics
See details and how to joinNCT07711418 · EU 2025-525129-11-00
Phase 1Taking people
A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.
Where
Gdansk, Wroclaw
Age
18 years to 64 years
People
291 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2025-523826-41-00 · EU 2025-523826-41-00
Phase 1Taking people
A first-in-human, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.
Where
Białystok, Janki, Katowice, Kielce, Ozarowice, Wroclaw
Age
18 years to 64 years
People
80 worldwide
Run by
Egle Therapeutics
See details and how to join2025-521658-40-00 · EU 2025-521658-40-00
Phase 2Taking people
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Where
Bydgoszcz, Chojnice, Gdansk, Katowice, Kielce, Lublin, Piotrkow Trybunalski, Poznan, Szczecin, Warsaw, Wroclaw
Age
18 years to 65 years
People
280 worldwide
Run by
Apollo Therapeutics Ltd
See details and how to joinNCT07599813
Phase 2Taking people
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
Where
Cracow, Gdansk, Katowice, Lodz, Lublin, Sosnowiec, Szczecin, Warsaw, Wroclaw
Age
18 years and over
People
175 worldwide
Run by
Apogee Therapeutics Inc.
See details and how to join2024-519795-11-00 · EU 2024-519795-11-00
Phase 2Taking people
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis
Where
Gdansk, Krakow, Lublin, Rzeszów, Sosnowiec, Tarnów, Warsaw
Age
6 months to 23 months
People
35 worldwide
Run by
Galderma R&D
See details and how to joinNCT07660835 · EU 2025-525027-27-00
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Where
Bialystok, Chorzów, Cracow, Gdansk, Katowice, Kielce, Lublin, Nowa Sol, Nowy Targ, Poznan, Sosnowiec, Szczecin, Tarnów, Warsaw, Warszawa, Wroclaw
Age
18 years to 74 years
People
405 worldwide
Run by
Inmagene LLC
See details and how to joinNCT07037901 · EU 2024-520117-50-00
No phaseTaking people
Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function
Where
Bialystok, Warsaw
Age
1 day to 14 days
People
400 worldwide
Run by
Société des Produits Nestlé (SPN)
See details and how to joinNCT06943469
Phase 2Taking people
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Where
Cracow, Łódź, Rzeszów, Szczecin, Warszawa, Wroclaw
Age
18 years and over
People
200 worldwide
Run by
Corvus Pharmaceuticals, Inc.
See details and how to joinNCT07441395 · EU 2025-524384-20-00
No phaseNot yet taking people in Poland
URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis
Where
Gdansk, Malbork
Age
18 years and over
People
44
Run by
CEN Biotech
See details and how to joinNCT07295678